Overview

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Levodopa